AstraZeneca PLC

AZN remains in a Stage 4 decline with a bearish medium-term bias after the support failure in mid-July. Price sits below the 9 and 20 EMAs and has been unable to reclaim these levels on the recent oversold bounce, suggesting sell-side control. The long-term uptrend is intact above the rising 200 DMA, capping risk, but rallies need to be watched for rejections at falling EMAs to maintain the bearish stance. A decisive reclaim and close above the EMAs would warrant a reassessment.

• ↑Q1 2025 revenue rose 10% YoY to $11.7 B; core EPS up 21% to $2.49.
• ↑Oncology sales jumped 16% YoY to $6.8 B, led by strong Infinzi uptake.
• ↓Wainua trial failure reduces near-term revenue visibility.